
Biomedical Scientist &
Drug Discovery
Samuel C.
Fehling, PhD
Preclinical Research & Translation
Designing rigorous in vitro and in vivo studies to evaluate targets, characterize therapeutics and support preclinical development decisions.
Assay Development & Screening
Building robust screening and characterization platforms for small molecules and antibodies, including kinetic analysis workflows.
Scientific Contributions & Impact
10+ years across industry and academia, with 11 peer-reviewed publications, 30+ molecular diagnostic assays developed and multiple therapeutic candidates.
About Sam
Senior Scientist with more than 10 years of experience in translational oncology, molecular diagnostics, preclinical pharmacology and discovery of small molecules and antibody therapeutics. Experienced in designing and executing in vitro and in vivo studies, validating targets, developing assays and collaborating across multidisciplinary teams to advance drug discovery programs.
Work Experience
BioCryst Pharmaceuticals, Inc.
Sr. Research Biologist
• July 2025 – Present
Preclinical Assay Validation
Designed and qualified total and free drug target assays on the Gyrolab xPlore platform for non-human primate (NHP) pharmacodynamic studies, authoring formal validation reports.
Regulatory Enablement
Accelerated preclinical pipelines by screening antibody candidates and generating figures and study reports to support Investigational New Drug (IND) filings.
Therapeutic Characterization
Performed surface plasmon resonance (SPR) kinetics and cross-reactivity assays on the Biacore T200 using Protein A and CM5 chips to evaluate antibody therapeutics.
Research Biologist
• December 2022 – July 2025
High-Throughput Screening
Screened and characterized the efficacy and mechanism of action of thousands of small molecule and antibody candidates using cell-based and cell-free in vitro assays to drive medicinal chemistry and protein science pipelines.
Pharmacodynamic Modeling
Evaluated rodent and NHP pharmacodynamics by analyzing plasma samples from treated models to quantify total and free protein expression levels.
BioGX, Inc.
Research & Development Scientist
• February 2020 – December 2022
Molecular Assay Engineering
Developed 30+ extraction-free, direct-addition PCR assays for custom and FDA EUA-approved diagnostic products including influenza, COVID-19 and Staphylococcus.
Instrumentation & Qualification
Executed end-to-end development and instrument qualifications (IQ/OQ/PQ) across BD MAX, QuantStudio, Bio-Rad and ABI 7500 platforms.
Quality Assurance & Data Modeling
Used QC risk assessments to validate outgoing commercial products, guide critical design decisions and train technical personnel.
University of Alabama at Birmingham
Graduate Research Assistant
• August 2014 – December 2019
Target Validation & Translational Oncology
Investigated preclinical research of BET and PARP inhibitors in pancreatic cancer and cholangiocarcinoma, resulting in 4 co-authored, peer-reviewed publications.
In Vivo & In Vitro Disease Modeling
Developed and maintained patient-derived xenograft (PDX) murine models, performing dosing schedules (oral gavage, IP injections) and establishing novel primary cell culture lines from patient tumors.
Measured Therapeutic Synergy
Used combinatorial treatments of BET inhibitors with chemotherapy both in vitro and in vivo to measure the synergy of therapeutics for cholangiocarcinoma and pancreatic cancer.
Technical Skills

Murine Mouse Models
Experienced with athymic nude & C57BL/6 mice, oral gavage, intraperitoneal (IP) injection and patient-derived xenograft (PDX) models.

In Vitro / Primary Cell Culture
Utilizing commercially available cell culture lines & developing primary cell culture lines from patient tumors.

Polymerase Chain Reaction (PCR)
Qualified in PCR platforms including BD MAX, Thermo Fisher QuantStudio, Bio-Rad CFX, ABI 7500, SmartCycler and BioGX Pixl.
Laboratory Techniques
- ELISA
- Western Blotting
- PCR and qPCR
- Surface Plasmon Resonance (SPR)
- Antibody Screening
- Target Validation
Preclinical Research
- Cell Culture (Immortalized and Primary)
- Patient-Derived Xenograft (PDX) Models
- Murine Xenograft Models
- Pharmacodynamic (PD) Studies
Instrumentation
- Gyrolab xPlore
- Biacore T200
- Bio-Rad CFX96 / 364
- Thermo Fisher QuantStudio
- ABI 7500
Scientific Software
- GraphPad Prism
- Biacore Evaluation Software
- Gyrolab Evaluator
- ImageJ (FIJI)
- Microsoft 365
Creative Projects

Computers & Technology
Self-hosted website infrastructure, Linux systems administration, Docker environments, networking and automation projects demonstrating technical problem-solving outside the laboratory. This website is self-hosted on my personal Raspberry Pi 4.

DJI & First-Person View (FPV) Drones
Pilot skilled in operating DJI drones for photography / videography & FPV drones for acrobatics / stunts. Competent in ad-hoc electronic repairs such as wiring & soldering.

Photography & Photo Editing
Photographer with expertise in Adobe Photoshop and Lightroom, adept in mirrorless, smartphone and drone photography with over 110 stock photos sold through Shutterstock & Getty.
Education
University of Alabama at Birmingham (UAB)
Ph.D. in Biomedical Sciences (Cancer Biology)
2014 – 2019
- Cancer Biology Newsletter Editorial Board
- Cancer Biology Student Seminar Co-Organizer
- Graduate Career Awareness and Trends (GCAT) Communications Director
University of Wisconsin – Eau Claire (UWEC)
B.S. in Biochemistry & Molecular Biology
2010 – 2014
- Biology Club Treasurer
- Molecular Movement Treasurer
Publications
11 Peer-Reviewed Articles with 410 Citations
Featured Publications
BET Inhibition Decreases HMGCS2 and Sensitizes Resistant Pancreatic Tumors to Gemcitabine
Aubrey L Miller, Samuel C Fehling, Rebecca B Vance, Dongquan Chen, Eric Josh Brown, M Iqbal Hossain, Eric O Heard, Shaida Andrabi, Hengbin Wang, Eddy S Yang, Donald J Buchsbaum, Robert CAM van Waardenburg, Susan L Bellis, Karina J Yoon.
Cancer Letters. 2024 June 28. (PMID: 38704133)
The BET Inhibitor JQ1 Augments the Antitumor Efficacy of Gemcitabine in Preclinical Models of Pancreatic Cancer
Aubrey L. Miller, Patrick L. Garcia, Samuel C. Fehling, Tracy L. Gamblin, Rebecca B. Vance, Leona N. Council, Dongquan Chen, Eddy S. Yang, Robert CAM van Waardenburg, Karina J. Yoon.
Cancers. 2021 July 11. (PMCID: PMC8303731)
The Combination of BET and PARP Inhibitors is Synergistic in Models of Cholangiocarcinoma
Samuel C. Fehling, Aubrey L. Miller, Patrick L. Garcia, Rebecca B. Vance, Karina J. Yoon.
Cancer Letters. 2019 October 9. (PMCID: PMC7017643)
The BET Inhibitor JQ1 Attenuates Double Strand Break Repair and Sensitizes Models of Pancreatic Ductal Adenocarcinoma to PARP Inhibitors
Miller AL, Fehling SC, Garcia PL, Gamblin TL, Council LN, van Waardenburg RCAM, Yang ES, Bradner JE, Yoon KJ.
EBioMedicine. 2019 June. (PMCID: PMC6604668)
FTY720 Enhances the Anti-Tumor Activity of Carboplatin and Tamoxifen in a Patient-Derived Xenograft Model of Ovarian Cancer
Kreitzburg KM, Fehling SC, Landen CN, Gamblin TL, Vance RB, Arend RC, Katre AA, Oliver PG, van Waardenburg RCAM, Alvarez RD, Yoon KJ.
Cancer Letters. 2018 August 15(18): 30527-5. (PMCID: PMC6756795)
MicroRNA-31 is Required for Astrocyte Specification
Meares GP, Rajbhandari R, Gerigk M, Tien CL, Chang C, Fehling SC, Rowse A, Mulhern KC, Nair S, Gray GK, Berbari NF, Bredel M, Benveniste EN, Nozell SE.
Glia. 2018 May, 66(5): 987-998. (PMCID: PMC5851835)
A Comparative Study of All-atom Molecular Dynamics Simulation…
Fehling SC, Strom AM, Lehman BP, Andrews RJ, Bhattacharyya S, Hati S.
American Journal of Undergraduate Research. 2017 June; 14(2): 27-44 (DOI: 10.33697/AJUR.2017.012)
Loss of SOCS3 in Myeloid Cells Prolongs Survival in a Syngeneic Model of Glioma
McFarland BC, Marks MP, Rowse AL, Fehling SC, Gerigk M, Qin H, Benveniste EN.
Oncotarget. 2016 April 12; 7(15): 20621-35. (PMCID: PMC4991480)
Loss of Tumor Suppressive microRNA-31 Enhances TRADD/NF-κB Signaling in Glioblastoma
Rajbhandari R, McFarland BC, Patel A, Gerigk M, Gray GK, Fehling SC, Bredel M, Berbari NF, Kim H, Marks MP, Meares GP, Sinha T, Chuang J, Benveniste EN, Nozell SE.
Oncotarget. 2015 July 10; 6(19): 17805-16. (PMCID: PMC4627347)
Comparison of Intrinsic Dynamics of Cytochrome p450 Proteins Using Normal Mode Analysis
Dorner ME, McMunn RD, Bartholow TG, Calhoon BE, Conlon MR, Dulli JM, Fehling SC, Fisher CR, Hodgson SW, Keenan SW, Kruger AN, Mabin JW, Mazula DL, Monte CA, Olthafer AG, Sexton AE, Soderholm BR, Strom AM, Hati S.
Protein Science. 2015 September; 24(9): 1495-507. (PMCID: PMC4570543)
Probing the Global and Local Dynamics of Aminoacyl-tRNA Synthetases using All-Atom and Coarse-Grained Simulations
Strom AM, Fehling SC, Bhattacharyya S, Hati S.
Journal of Molecular Modeling. 2014 May; 20(5): 2245 (PMCID: PMC4030129)
Contact
LinkedIn • Google Scholar • GitHub • ORCID • ResearchGate
Open to Scientist, Senior Scientist, Principal Scientist and Translational Research opportunities in oncology, immunology and drug discovery.
Open to relocation.
Email: [email protected]
Outside the Lab
I Love Exploring Our National Parks and Road Tripping Across the Country. Full Stories Can Be Found On Our Travel Blog, With Each Mile











